Josep M. Llovet, MD is ICREA Research Prof, Liver Cancer Translational Oncology Lab, Liver Unit, IDIBAPS, Hospital Clinic, Univ. Barcelona, Prof.of Medicine and Director of the Liver Cancer Program at Icahn Mount Sinai School of Medicine, NY. He has published 287 manuscripts in Liver Cancer, including NEJM, Lancet, Nature, Nat.Genet., Cancer Cell and Gastroenterology (IF:4052;citations:66339;h-index:105). Top 1% most cited researcher globally, Clarivate Analytics (2014-19), Educational Councilor (2013-15), President of ILCA (2011-13), Senior Editor of CCR, he has lectured in more than 604 international meetings and has been the PI of European grants FP7-HEPTROMIC,HEP-CAR, Accelerator Award, NIH-NIDDK R01-award, I+D and competitive private grants. His achievements are: 1.Establish a clinical and molecular classification for HCC. 2.Establish efficacy of chemoembolization and sorafenib for HCC.3.Identification of novel drivers and oncogenic pathways in HCC and ICC.
Prof Josep M. Llovet has been working in clinical and translational research in hepatocellular carcinoma (HCC) and cholangiocarcinoma (ICC) for the last 25 years. He is leading international randomized trials in HCC on novel targeted therapies and developing a molecular classification of the disease, understanding the genetic aberrations and signaling pathways involved and in the identification of new molecular targeted therapies. He has organized the HCC Genomic Consortium and the HEPTROMIC Consortium that includes several international HCC research centers: IDIBAPS-Hospital Clínic, Icahn School of Medicine at Mount Sinai, INSERM, Univ. Tuebingen, Dana-Farber-MIT-Broad Institute and NCI. The main future areas of interest are a) identify biomarkers predicting response to sorafenib and checkpoint inhibitors (nivolumab) or mechanisms of resistance b) translate oncogenic drivers discoveries as targeted therapies in HCC and ICC, c) unraveling the molecular traits of NASH-HCC.
– Pinyol R, Montal R, Bassaganyas L et al. 2019, ‘Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial‘,Gut. 68:1065-1075
– Malehmir M, Pfister D, Gallage S et al. 2019, ‘Platelet GPIb alpha is a mediator and potential interventional target for NASH and subsequent liver cancer’, Nature Medicine, 25:641-655.
– Moeini A, Torrecilla S, Tovar V et al. 2019, ‘An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents’, Gastroenterology,57:1383-1397
– Montal R, Andreu-Oller C, Bassaganyas L et al. 2019, ‘Molecular Portrait of High Alpha-Fetoprotein in Hepatocellular Carcinoma; Implications for Biomarker-Driven Clinical Trials’, British Journal of Cancer, 121:340-343
– Ruiz de Galarreta M, Bresnahan E, Molina-Sanchez P et al. 2019, ‘beta-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma’, Cancer Discovery, 9:1124-1141
– Teufel M, Seidel H, Koechert K et al. 2019, ‘Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma’, Gastroenterology, 56:1731-1741
– Pinyol R, Sia D & Llovet JM 2019, ‘Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC’, Clinical Cancer Research. 25:2021-2023
– Llovet JM, Montal R & Villanueva A 2019, ‘Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival’, Journal Of Hepatology, 70:1262-1277
Selected research activities
- Senior Editor. Clinical Cancer Research
- Director. Master in Translational Medicine. Universitat de Barcelona
- Executive Committee. IDIBAPS
- Director Liver Cancer Program. ICAHN School of Medicine at Mount Sinai
- Fellow Award. American Association for the Study of the Liver Diseases (AASLD)
- Tisch Cancer Institute Award. NCI designated Cancer Center Recognition ISMMS
- President, AASLD-SIG Liver Tumors